Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 15/20 | 0.71 |
| ▸ | TACR2 | P21452 | 14/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.53 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6650281 | 0.94 | TACR3 (0.64) | TACR3TACR2OPRM1CYP2C9TRPV4 | |
| SCHEMBL5909008 | 0.89 | TACR3 (0.68) | TACR3TACR2OPRM1CYP2C9TRPV4 | |
| SCHEMBL5908992 | 0.89 | TACR3 (0.68) | TACR3TACR2OPRM1CYP2C9TRPV4 | |
| SCHEMBL1581445 | 0.88 | TACR3 (0.69) | TACR3TACR2OPRM1CYP2C9TRPV4 | |
| SCHEMBL14564772 | 0.88 | CYP2C9 (0.77) | TACR3TACR2OPRM1CYP2C9TRPV4 | |
| SCHEMBL1581261 | 0.87 | TACR3 (0.68) | TACR3TACR2OPRM1CYP2C9TRPV4 | |
| SCHEMBL8268049 | 0.87 | TACR3 (0.68) | TACR3TACR2OPRM1CYP2C9TRPV4 | |
| SCHEMBL5425877 | 0.86 | CYP2C9 (0.75) | TACR3TACR2OPRM1CYP2C9NTRK1 | |
| SCHEMBL1580919 | 0.86 | TACR3 (0.67) | TACR3TACR2OPRM1CYP2C9TRPV4 | |
| SCHEMBL1581440 | 0.86 | TACR3 (0.67) | TACR3TACR2OPRM1CYP2C9TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259882-A1 | 3-SUBSTITUTED QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. | 2007-11-08 | — | — | US | disclosed |
| US-20070161647-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. | 2007-07-12 | — | — | US | disclosed |
| US-20060229315-A1 | 3-Substituted Quinoline-4-Carboxamide Derivatives as NK-3 and NK-2 Receptor Antagonists | GLAXOSMITHKLINE S.P.A. (IT) | 2006-10-12 | — | — | US | disclosed |
| EP-1659120-A1 | 3-substituted quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | GlaxoSmithKline S.p.A. (IT) | 2006-05-24 | — | — | EP | disclosed |
| EP-1385839-B1 | 3-SUBSTITUTED QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE SPA (IT) | 2006-02-22 | — | — | EP | disclosed |
| EP-1377567-B1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE SPA (IT) | 2005-12-21 | — | — | EP | disclosed |
| US-20050176762-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | GLAXOSMITHKLINE SPA | 2005-08-11 | — | — | US | disclosed |
| US-20040180902-A1 | 3-Substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | SMITHKLINE BEECHAM S.P.A. (IT) | 2004-09-16 | — | — | US | disclosed |
| US-20040152726-A1 | Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | SMITHKLINE BEECHAM S.P.A. (IT) | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180902-A1 | 3-Substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | HRH4, HRH2, HRH3 | TACR3 60/4885TACR2 6/4885OPRM1 224/4885 |
| US-20040152726-A1 | Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | KCNH2, KCNH3, KCNJ8 | TACR3 149/4885TACR2 56/4885OPRM1 374/4885 |
| US-20070161647-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS | KCNQ3, KCNK3, KCNK2 | TACR3 45/4885TACR2 22/4885OPRM1 733/4885 |
| US-20070259882-A1 | 3-SUBSTITUTED QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | KCNK3, KCNJ2, KCNK2 | TACR3 19/4885TACR2 12/4885OPRM1 756/4885 |
| US-20060229315-A1 | 3-Substituted Quinoline-4-Carboxamide Derivatives as NK-3 and NK-2 Receptor Antagonists | KCNK3, KCNJ2, KCNK2 | TACR3 19/4885TACR2 12/4885OPRM1 756/4885 |
| US-20050176762-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | KCNQ3, KCNK3, KCNK2 | TACR3 45/4885TACR2 22/4885OPRM1 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.